logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients

Exelixis (EXEL) announced its initiation of a phase 3 pivotal trial (COSMIC-311) of Cabometyx (cabozantinib) in patients with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies . The co-primary endpoints for...

Read More

October 9, 2018

0

Agenus: Why Canceling Prophage Trial Should Not be Concerning

Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore with Agenus’ totally changed status now with its new immunotherapy pipeline. The new checkpoint inhibitors products and their checkpoint targets products are the talk...

Read More

February 22, 2017

0

Amgen's product Amgevita, a biosimilar to adalimumab, will be launched in the European market today.

Amgen (AMGN) announced that Amgevita TM , a biosimilar to adalimumab , will launch in markets across Europe  beginning on October 16, 2018 . According to Amgen’s press release, Amgevita TM  is the first adalimumab biosimilar to be approved by the European Commission ...

Read More

October 16, 2018

0

An Erroneous Interpretation of an Outstanding Achievement in CRISPR Gene Editing

A False Reason for Unwarranted Selling of CRISPR/Cas9 Gene Editing Shares     CRISPRs  are bacterial immune systems that contain many defense enzymes such as the Cas9 “molecular scissors,” which scientists have engineered as  a   powerful DNA-targeting gene-editing tool  ...

Read More

March 28, 2018

0

Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial

Bellicum Pharmaceuticals (BLCM) :  The U.S. Food and Drug Administration (FDA) has l ifted the clinical hold on studies of BPX-501  in the U.S. The decision follows consultation with the FDA and agreement on amendments to the study protocols including guidance on monitoring and...

Read More

April 12, 2018

0

Alleviating osteoarthritis pain without the need for opioid drugs

Tanezumab , an investigational humanized monoclonal antibody developed by Pfizer (PFE) and Eli Lilly (LLY), met all three co-primary endpoints in patients with osteoarthritis (OA) . The 16-week Phase 3 study, which evaluated subcutaneous administration of tanezumab in patients with...

Read More

October 25, 2018

0

OncoCyte's Liquid Biopsy Test Has Positive News

OncoCyte (OCX) has news. This firm, which develops non-invasive blood and urine liquid biopsy diagnostic tests has good news about its lung cancer liquid biopsy. Liquid biopsy is a term recently coined for a simple blood test that can replace...

Read More

March 15, 2017

0

Let’s Go Shopping

In today’s news,  Incyte’s (INCY)  immuno-oncology IDO1 inhibitor product Epacadostat in combination with Merck’s immuno-oncology product Keytruda ®  did not meet the endpoints of the trial in patients with unresectable or metastatic melanoma. The stock was subjected to a selloff...

Read More

April 6, 2018

0

Neurocrine BioSciences (NBIX): Time for Transformation and Achievements

Positive Results of INGREZZA on Tardive Dyskinesia Highlights Neurocrine Biosciences Sciences and Scientists      The results published online by The American Journal of Psychiatry demonstrate that Phase 3 trial with Neurocrine Biosciences (NBIX) drug Ingrezza conducted on patients with...

Read More

March 27, 2017

0

Alnylam’s RNAi Product Patisiran Has More Positive News

The Market The Stock Market is Still under pressure, which is frightening common investors, pressuring them to sell. We see no real reasons for the stock market to be acting as a Bear when the criteria of bullishness are obvious...

Read More

April 25, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 47
  • 48
  • 49
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy